Bryn Mawr Capital Management LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Bryn Mawr Capital Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 52.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,058 shares of the company’s stock after buying an additional 1,732 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Eli Lilly and Company were worth $2,948,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of LLY. International Assets Investment Management LLC grew its position in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the last quarter. Sapient Capital LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $435,736,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after purchasing an additional 645,473 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $8.64 during trading on Friday, hitting $733.51. 1,998,801 shares of the company were exchanged, compared to its average volume of 3,021,320. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78. The stock has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.60 and a beta of 0.34. The firm has a 50 day moving average price of $761.79 and a 200 day moving average price of $666.06.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 EPS. On average, equities analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LLY. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.